Sign in Get iMD Health

iMD Health Newsletter: August 2018

In This Issue:

Your Go-To Cold Sore Treatment

Cold sores (herpes simplex virus 1) are a bothersome reality for many people. Although they’re not dangerous, they can make it hard to enjoy everyday life.

Read on to learn about the virus, understand the triggers, and get tips on how your patients can Act On It fast with Abreva.

If you already have an account on the iMD Patient Engagement Platform, CLICK HERE to educate your patients using our Cold Sore condition topic!

To register for a free iMD account, CLICK HERE.

Cold Sores 101

67% of the population under age 50 has HSV-1 because it is so contagious. There’s no cure for the cold sore virus – once a person is infected, the virus never leaves their body. 

For the majority of people, HSV-1 remains inactive throughout their lives and they may never know they have the virus. Around 1 in 4 people will experience recurrent infections.

61% of frequent cold sore sufferers say that cold sores are a severe problem for them.

Knowledge is a patient’s best strategy for managing cold sore outbreaks. Here are a few things to share with your patients so they can treat their next cold sore effectively and efficiently.

Take the cold sore trigger quiz on abreva.ca to learn more.

Advantages of Abreva

Abreva contains 10% docosanol, a viral-blocking agent that modifies the cell membrane to inhibit the virus from infecting healthy skin cells. That translates into all kinds of real results that you’ll both feel and see.

To learn more about cold sores and Abreva, visit abreva.ca.

**Abreva is proven to reduce healing time of cold sores to median 4.1 days when used at the first sign of a cold sore. An untreated cold sore can last approximately 8 days.

Trademarks owned or licensed by GSK. ©2018 GSK or licensor.

If you already have an account on the iMD Patient Engagement Platform, CLICK HERE to educate your patients using our Cold Sore condition topic!

To register for a free iMD account, CLICK HERE.

What’s New on iMD?

RestoraLAX content can be found under the constipation condition area and features Patient Information, a $3 off coupon and a Trial Offer for your patients through their website www.restoralax.ca!

Attention Pharmacists! Complete the Basaglar Biosimilars Program on iMD by August 15, 2018* and receive a CCCEP accreditation! Access this program in eLearning on your iMD home screen. 

*Program will still be available on iMD after August 15, 2018.

Basaglar content can be found under the Type 1 Diabetes and Type 2 Diabetes condition areas. Includes usage guide, KwikPen instructions, safety information and quick injection tips. CLICK HERE to view. 

A reminder that you can continue to access Finacea’s patient content under the Rosacea condition area on iMD Health. CLICK HERE to view.

See What Else is New on iMD

Take Me to My iMD Account

Sign Up for a Free iMD Account